Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Igm Biosciences Inc (IGMS)

Igm Biosciences Inc (IGMS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Change in Medivir's Board of Directors PR Newswire - Fri Oct 20, 2023

/PRNewswire/ -- Medivir AB (Nasdaq: MVIR) and (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

IGMS : 9.77 (+1.45%)
Fostrox + Lenvima continues to show promising tumor control in HCC, all patients have now dosed at least two treatment cycles PR Newswire - Thu Oct 5, 2023

/PRNewswire/ -- Medivir AB (Nasdaq:MVIR) (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high...

IGMS : 9.77 (+1.45%)
Medivir to present at the Pareto Securities Healthcare Conference PR Newswire - Thu Sep 14, 2023

/PRNewswire/ -- Medivir AB (Nasdaq: MVIR) (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high...

IGMS : 9.77 (+1.45%)
Medivir's Partner Tango Therapeutics received FDA clearance to start the TNG348 phase 1/2 clinical study PR Newswire - Mon Sep 11, 2023

/PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

IGMS : 9.77 (+1.45%)
Medivir presents data on additive activity of fostrox in combination with Lenvima or sorafenib in non-clinical tumor models at ILCA PR Newswire - Thu Sep 7, 2023

/PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancers with high unmet medical...

IGMS : 9.77 (+1.45%)
Medivir reports promising interim data, including a first complete response in phase 1b/2a HCC study with fostrox in combination with Lenvima PR Newswire - Mon Sep 4, 2023

/PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

IGMS : 9.77 (+1.45%)
Medivir Hosts Expert Perspectives Webcast on the Evolving Treatment Landscape and the Unique Treatment Challenges in HCC PR Newswire - Fri Sep 1, 2023

/PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

IGMS : 9.77 (+1.45%)
Medivir to present at the Erik Penser Bank Company Event PR Newswire - Wed Aug 23, 2023

/PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

IGMS : 9.77 (+1.45%)
Promising tumor control for fostrox in combination with Lenvima in ongoing phase 2a study in HCC, 15th patient included PR Newswire - Mon Aug 14, 2023

/PRNewswire/ -- Medivir AB (Nasdaq: MVIR) (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high...

IGMS : 9.77 (+1.45%)
Medivir partners with world-leading liver cancer experts in new Scientific Advisory Council PR Newswire - Mon Aug 7, 2023

/PRNewswire/ -- Medivir AB (Nasdaq: MVIR) (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high...

IGMS : 9.77 (+1.45%)

Barchart Exclusives

Is MicroStrategy Headed for S&P 500 Eligibility? Barchart - Wed May 1, 7:16AM CDT
MicroStrategy is a tech stock with significant exposure to Bitcoin, tying its share prices to the digital asset. However, one analyst thinks MSTR should be targeting the benchmark S&P 500 Index. Let's see why. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot